PG
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants | Frontiers in pharmacology |  | 2026 | 1 | 0 | ||
| Cytochrome P450 phenotyping using the Geneva cocktail improves metabolic capacity prediction in a hospitalized patient population | British journal of clinical pharmacology |  | 2025 | 44 | 0 | ||
| Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling | Clinical pharmacokinetics | | 2025 | 64 | 84 | ||
| Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban | British journal of clinical pharmacology | | 2025 | 75 | 0 | ||
| Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serum | European journal of neuroscience | | 2024 | 84 | 171 | ||
| Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side | CPT: pharmacometrics & systems pharmacology | | 2023 | 143 | 372 | ||
| Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study | CPT: pharmacometrics & systems pharmacology | | 2023 | 132 | 332 | ||
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | | 2022 | 154 | 133 | ||
| Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting | Journal of personalized medicine | | 2022 | 225 | 323 | ||
| Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities | Clinical pharmacology and therapeutics | | 2022 | 180 | 375 | ||
| Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients | Acta Physiologica | | 2021 | 399 | 3 |
